Compare · OSUR vs VRAX
OSUR vs VRAX
Side-by-side comparison of OraSure Technologies Inc. (OSUR) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. OSUR focuses on Medical/Dental Instruments, while VRAX focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances.
- OSUR is the larger of the two at $242.4M, about 402.2x VRAX ($602,555).
- OSUR has been more active in the news (6 items in the past 4 weeks vs 4 for VRAX).
- OSUR has more recent analyst coverage (5 ratings vs 1 for VRAX).
- Company
- OraSure Technologies Inc.
- Virax Biolabs Group Limited
- Price
- -
- -
- Market cap
- $242.4M
- $602,555
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 6
- 4
- Recent ratings
- 5
- 1
OraSure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
Latest OSUR
- Amendment: SEC Form 10-Q/A filed by OraSure Technologies Inc.
- SEC Form 10-Q filed by OraSure Technologies Inc.
- OraSure Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
- Amendment: SEC Form SCHEDULE 13G/A filed by OraSure Technologies Inc.
- OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th
- Director Boyd Steven Kyle was granted 4,797 shares, increasing direct ownership by 3% to 168,031 units (SEC Form 4)
- Director Kenny John P. covered exercise/tax liability with 5,116 shares, decreasing direct ownership by 2% to 204,598 units (SEC Form 4)
- SEC Form S-8 filed by OraSure Technologies Inc.
- SEC Form 10-Q filed by OraSure Technologies Inc.
Latest VRAX
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
- SEC Form 3 filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 424B5 filed by Virax Biolabs Group Limited
- SEC Form EFFECT filed by Virax Biolabs Group Limited
- Amendment: SEC Form F-3/A filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited